UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

  

Form 6-K

  

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of December 2018

Commission File Number 001-38370

  

CollPlant Holdings Ltd.

(Exact name of registrant as specified in its charter)

  

3 Sapir Street, Weizmann Science Park

Ness Ziona 74140, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒          Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐ 

 

 

 

 

  

Attached hereto as Exhibit 99.1 and incorporated by reference herein is a press release issued by the Registrant entitled “Clinical Trial Published in the Journal of Shoulder and Elbow Surgery Concludes that CollPlant’s Vergenix™ STR Effectively Demonstrates Significant Clinical Improvements in Tennis Elbow”.

 

 Exhibit Index

 

Exhibit No.   Description
     
99.1   Press Release, dated December 10, 2018

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  COLLPLANT HOLDINGS LTD.
     
Date: December 10, 2018 By:    /s/ Eran Rotem
    Name: Eran Rotem
    Title:   Deputy CEO and Chief Financial Officer

 

 

2